Business Context and Reporting Period
This Form 6-K filing by Quoin Pharmaceuticals Ltd. covers the month of June 2022, with a report date of June 13, 2022. The filing addresses regulatory notifications received from The Nasdaq Stock Market regarding the Company's compliance with listing standards.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on regulatory compliance status rather than financial performance data.
Material Changes and Regulatory Status
- Minimum Bid Price Deficiency: On June 10, 2022, the Company received notice that its American Depositary Share (ADS) closing bid price fell below the required $1.00 minimum for 30 consecutive business days.
- Compliance Period: The Company has 180 calendar days, until December 7, 2022, to regain compliance. Compliance is achieved if the closing bid price is at least $1.00 for 10 consecutive business days.
- Stockholders' Equity Deficiency: As previously reported on April 22, 2022, the Company was notified of non-compliance with the minimum stockholders' equity requirement. A compliance plan was submitted within the required 45-day window.
Outlook, Risks, and Management Commentary
Management states that while the Nasdaq notifications do not immediately affect the Company's listing status, there is no assurance that the Company will successfully regain compliance with either the minimum stockholders' equity or minimum bid-price requirements. Failure to comply by December 7, 2022, may result in delisting unless the Company qualifies for an additional 180-day grace period by meeting other initial listing standards for the Nasdaq Capital Market.
Investor Verification Checklist
- Verify the current closing bid price of Quoin Pharmaceuticals ADSs to assess progress toward the $1.00 threshold.
- Confirm the status of the compliance plan submitted regarding the minimum stockholders' equity requirement.
- Monitor for any further correspondence from Nasdaq regarding the acceptance of the compliance plan or potential delisting actions.
- Review the Company's most recent audited financial statements to understand the underlying causes of the equity deficiency.